Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study
Morteza Jafarinia
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorMohammad-Reza Mohammadi
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorAmirhossein Modabbernia
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorMandana Ashrafi
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorDanial Khajavi
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorMina Tabrizi
Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorNoorollah Yadegari
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorCorresponding Author
Shahin Akhondzadeh
- [email protected]
- 98-21-88281866 | Fax: +98-21-55419113
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Shahin Akhondzadeh, Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337, Iran. Tel: +98-21-88281866; Fax: +98-21-55419113. E-mail: [email protected]Search for more papers by this authorMorteza Jafarinia
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorMohammad-Reza Mohammadi
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorAmirhossein Modabbernia
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorMandana Ashrafi
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorDanial Khajavi
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorMina Tabrizi
Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorNoorollah Yadegari
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Search for more papers by this authorCorresponding Author
Shahin Akhondzadeh
- [email protected]
- 98-21-88281866 | Fax: +98-21-55419113
Psychiatric Research Centre, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
Shahin Akhondzadeh, Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337, Iran. Tel: +98-21-88281866; Fax: +98-21-55419113. E-mail: [email protected]Search for more papers by this authorAbstract
Objective
To compare the safety and efficacy of bupropion with methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Methods
In a 6-week randomized double-blind study, 44 patients with a DSM-IV-TR diagnosis of ADHD were randomly assigned to receive bupropion 100–150 mg/day (100 mg/day for <30 kg and 150 mg/day for >30 kg) or methylphenidate 20–30 mg/day. Symptoms were assessed using Teacher and Parent Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) at baseline and weeks 3 and 6.
Results
Forty patients had at least one post-baseline measurement, and 38 patients completed the trial. No significant difference was found between the two groups on the Parent and Teacher ADHD-RS-IV scores ([F(1, 38) = 0.266, p = 0.609] and [F(1, 38) = 0.001, p = 0.972], respectively). By week 6, 18 patients (90%) in each group achieved response on the Parent scale (Fisher's exact test p-value = 1.0). With the Teacher ADHD-RS-IV used, eight (40%) patients in the bupropion group and 12 (60%) patients in the methylphenidate group achieved response by week 6 (χ2(1) = 1.600, p = 0.206). Headache was observed more frequently in the methylphenidate group. Frequency of other side effects was not significantly different between the two groups.
Conclusions
Bupropion has a comparable safety and efficacy profile with methylphenidate in children and adolescents with ADHD. Copyright © 2012 John Wiley & Sons, Ltd.
Supporting Information
Supporting information may be found in the online version of this article.
| Filename | Description |
|---|---|
| hup_2242_supplementary_information.docWord document, 216.5 KB | Supporting information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, Laplant RJ. 1993. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 91: 1101–1106.
- Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. 2003. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27: 841–845.
- Akhondzadeh S, Mohammadi MR, Khademi M. 2004. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry 4: 9.
- Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. 2008. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 32: 145–149.
- Arnsten AF. 2006. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 31: 2376–2383.
- Ascher JA, Cole JO, Colin JN, et al. 1995. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56: 395–401.
- Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. 2004. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(Suppl 1): I102–I116.
- Barrickman LL, Perry PJ, Allen AJ, et al. 1995. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34: 649–657.
- Biederman J. 1998. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 59(Suppl 7): 4–16.
- Cantwell DP. 1998. ADHD through the life span: the role of bupropion in treatment. J Clin Psychiatry 59(Suppl 4): 92–94.
- Casat CD, Pleasants DZ, Van Wyck Fleet J. 1987. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull 23: 120–122.
- Conners CK, Casat CD, Gualtieri CT, et al. 1996. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35: 1314–1321.
- Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. 2001. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40: 307–314.
- Dupaul GJ, Power TJ, Anastopoulos AD, Reid R. 1998. ADHD Rating Scale—IV: Checklists, norms, and clinical interpretation. Guilford Press: New York.
- Ghanizadeh A, Mohammadi MR, Yazdanshenas A. 2006. Psychometric properties of the Farsi translation of the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version. BMC Psychiatry 6: 10.
- Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S. 2009. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 168: 234–237.
- Kuperman S, Perry PJ, Gaffney GR, et al. 2001. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 13: 129–134.
- Lee MS, Yang JW, Ko YH, et al. 2008. Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder. Child Psychiatry Hum Dev 39: 201–209.
- Levin FR, Evans SM, Mcdowell DM, Brooks DJ, Nunes E. 2002. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis 21: 1–16.
- Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. 2006. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 81: 137–148.
- Maneeton N, Maneeton B, Srisurapanont M, Martin SD. 2011. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci 65: 611–617.
- Mohammadi MR, Akhondzadeh S. 2007. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Rev Neurother 7: 195–201.
- Mohammadi M, Akhondzadeh S. 2011. Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy. Acta Med Iran 49: 487–498.
- Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S. 2010. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Hum Psychopharmacol 25: 560–565.
- Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J. 2007. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. J Clin Psychiatry 68: 1094–1101.
- Olvera RL, Pliszka SR, Luh J, Tatum R. 1996. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 6: 241–250.
- Paul M. 2008. Bupropion. In xPharm: The Comprehensive Pharmacology Reference, Editors-in-chief: Enna sj, BB David (eds). Elsevier: New York.
- Pliszka SR. 2003. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr 8: 253–258.
- Polanczyk G, De Lima MS, Horta BL, Biederman J, Rohde LA. 2007. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164: 942–948.
- Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED. 2005. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Neuropsychiatr Dis Treat 1: 245–251.
- Riggs PD, Leon SL, Mikulich SK, Pottle LC. 1998. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 37: 1271–1278.
- Schachter HM, Pham B, King J, Langford S, Moher D. 2001. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165: 1475–1488.
- Solhkhah R, Wilens TE, Daly J, Prince JB, Van Patten SL, Biederman J. 2005. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 15: 777–786.
- Spencer T, Biederman J, Steingard R, Wilens T. 1993. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 32: 211–214.
- Spencer T, Biederman J, Wilens T. 2004. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27: 373–383.
- Upadhyaya HP, Brady KT, Wang W. 2004. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study. J Am Acad Child Adolesc Psychiatry 43: 199–205.
- Waxmonsky JG. 2005. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol 6: 262–276.
- Wilens TE, Spencer TJ, Biederman J, et al. 2001. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158: 282–288.
